Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11460MR)

This product GTTS-WQ11460MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11460MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9228MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ10936MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ3564MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ13455MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ3655MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ4324MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ9044MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ12109MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW